EAU 2017: 4th ESO Prostate Cancer Observatory: The Radiation Oncologist’s Perspective

London, England. The esteemed Dr. Bolla provided the radiation oncologist’s perspective at this morning’s EAU 2017’s 4th ESO Prostate Cancer Observatory: Innovation and Care in the Next 12 Months. Dr. Bolla started by highlighting that there are now three randomized phase III trials showing that moderate hypofractionation (2.5-3.4 Gy per fraction) delivered with 3D conformal radiotherapy (3D-CRT) with or without intensity modulation is equivalent to low conventional fractionation (2 Gy/fraction) for men with low and intermediate risk prostate cancer with regard to treatment efficacy. Additionally, this treatment regimen is associated with decreased toxicity, cost and treatment duration.